Background
==========

The prevalence of diabetes mellitus (DM) for all age groups worldwide was estimated to be 2.8% in year 2000 and it is quite clear that male patients with DM are 3 times more likely to develop erectile dysfunction (ED) than those who do not have DM \[[@b1-medscimonit-21-94],[@b2-medscimonit-21-94]\]. In streptozotocin (STZ)-induced diabetic rats, hypogonadism was often observed \[[@b3-medscimonit-21-94]\]. Thus, the erectile process has been shown to be strongly androgen-sensitive, at least in the rat model \[[@b4-medscimonit-21-94]\]. Testosterone substitution can reverse hypogonadism and diabetes-induced penile hyporeactivity to cavernous nerve stimulation *in vivo* in rats, along with increased neuronal nitric oxide synthase (nNOS) expression \[[@b4-medscimonit-21-94]\]. Insulin-like growth factor binding protein-3 (IGFBP-3) is a member of the growth factor family and it is generally believed that the increased expression of IGFBP-3 is associated with ED in diabetic rats \[[@b5-medscimonit-21-94],[@b6-medscimonit-21-94]\], while IGFBP expression is suppressed by androgens \[[@b7-medscimonit-21-94]\].

It is well known that short hairpin RNA (shRNA) is emerging as a technology to silence gene expression by inhibiting mRNA translation and/or inducing its degradation, including in the penis \[[@b8-medscimonit-21-94]\]. In the current study, we investigated whether short hairpin ribonucleic acid constructs targeting IGFBP-3 (IGFBP-3 shRNA) can rehabilitate decreased testosterone concentrations in STZ-induced diabetic rats.

Material and Methods
====================

IGFBP-3 shRNA Constructs
------------------------

To design IGFBP-3 shRNA construct, the rat IGFBP-3 gene sequence (GI: M31837) was analyzed for a potential siRNA target using the web-based siRNA target finder and design tool provided on the Ambion website (Ambion, Inc., Austin, TX). Double-stranded siRNAs (nucleotide position: 611) were transcribed *in vitro* using the Silencer siRNA construction kit (Ambion) following the manufacturer's instructions. The inhibitory siRNA (5′-GCGCTACAAAGTTGACTATGA-3′, nucleotide position 611) was then cloned into the pGPU6/GFP/Neo plasmid vector (2^nd^ version, Ambion) as a short hairpin DNA sequence (5′ sense strand: 5′-CACCGCGCTACAAAGTTGACTATGATT CAAGAGATCATAGTCAACTTTGTAGCGCTTTTTTG-3′) according to the manufacturer's instructions. The pGPU6/GFP/Neo- IGFBP-3 shRNA plasmid was purified using the Endo-free Maxi kit (Qiagen, Valencia, CA). Plasmids were quantitated by spectrophotometry and prepared in 0.9% saline solution at a concentration of 1.0 μg/μL.

Experimental animals
--------------------

Twenty-seven adult SPF male Wistar rats (age 3 months, weight 310--330 g, certificated No. scxk\[E\]2008-0005) were obtained from Hubei Laboratory Animal of Research Center (Wuhan, China). The Wuhan University Animal Care and Use Committee approved all procedures in the current study. All rats were randomly divided into 3 groups with 9 rats each. Group 1 included 9 age-matched control rats that received i.p. injections of citrate buffer (100 mmol/L citric acid and 200 mmol/L disodium phosphate, pH 7.0). The other 18 rats all received i.p. injection of STZ at a dose of 65 mg/kg. Rats were considered diabetic if blood glucose levels were greater than 200 mg/dL ([Table 1](#t1-medscimonit-21-94){ref-type="table"}). Animals received 60 μl citrate buffer (Group 1 and 2) and 60 ul lipofectamine-plasmid complex (10 μg/kg) (Group 3) into the corpus cavernosum 12 weeks after STZ induction. Half the dose was administered in each crus. During intracavernosal injection, a constriction band was applied at the base of the penis, and the needle was left in place for 5 min to allow the medication to diffuse throughout the cavernous space \[[@b9-medscimonit-21-94]\].

Measurement of erectile responses
---------------------------------

At 12 weeks after IGFBP-3 shRNA administration, erectile function was evaluated by measuring intracavernous pressure (ICP) following electrostimulation of the cavernous nerves, as previously described \[[@b9-medscimonit-21-94]\]. The ratio of maximal ICP-to-mean arterial pressure (MAP) (ICP/MAP) and total ICP (area under curve) were recorded for each rat. All rats were the sacrificed with an i.p. overdose of pentobarbital (80 mg/kg). The penile shaft was collected for further analyses and whole blood samples from both systemic and penile shaft were also collected with serum obtained after clotting for 30 min at room temperature following centrifugation. All the serum samples were immediately snap-frozen in liquid nitrogen after collection and stored at −80°C for further analyses.

Quantitative real-time PCR analysis
-----------------------------------

Total RNA was extracted from rat penile samples using TRIzol™ reagent (Invitrogen, Merelbeke, Belgium) according to the manufacturer's protocol and re-suspended in RNAse-free water. Total RNA was stored at −80°C until analysis of IGFBP-3 mRNA levels by MyiQ single-color real-time PCR detection system (Bio-Rad laboratories, Hercules, CA) with the following primers:

IGFBP-3, forward 5′-AGCCGTCTCCTGGAAACACC-3′ and reverse 5′-CCCGCTTTCTGCCTTTGG-3′;

Quantitative mRNA measurements were performed in triplicate and normalized to an internal control of GAPDH. After the PCR program, data were analyzed with ABI 7300 SDS software (Applied Biosystems, Foster City, CA).

Western blot analysis
---------------------

The rat penile samples were lysed in RIPA buffer (1×TBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 0.004% sodium azide, 10 μl/ml PMSF, 10 μl/ml protease inhibitor cocktail, 10 μl/ml sodium orthovanadate). Protein concentration was measured using the Coomassie Plus Protein Assay Reagent™ (Pierce Biotechnology, Rockford, IL). Equal quantities (30 μg) of lysates were separated on 10% sodium dodecyl sulfate gradient polyacrylamide gels and electro-blotted onto PVDF membranes (Bio-Rad, Hercules, CA). The membranes were blocked and then incubated with rabbit anti-IGFBP-3 antibody (Sc-9028) at 1:1000 dilutions (Santa Cruz Biotechnology, Santa Cruz, CA). Chemiluminescence was detected using ECL Western blotting detection reagents (Amersham, Buckinghamshire, UK). The expression of IGFBP-3 protein was visualized by densitometry using the Mivnt Image analysis system (Shanghai Institute of Optical Instruments, Shanghai, China).

Enzyme-linked immunosorbent assay
---------------------------------

The measurement of serum testosterone concentration in penile tissue was performed using an enzyme-linked immunosorbent assay (ELISA) testosterone detection kit (R&D Systems, Minneapolis, MN). Similarly the measurement of cGMP concentration in penile tissue was performed using an enzyme-linked immunosorbent assay (ELISA) cGMP detection kit (R&D Systems, Minneapolis, MN).

Statistical analysis
--------------------

Data are expressed as mean ±SD. Differences among normal control group, diabetic control group, and IGFBP-3 shRNA treatment group were considered significant at the level of *p\<0.05* using the 2-tailed unpaired *t* test.

Results
=======

Evaluation of erectile function
-------------------------------

We determined the ratio of ICP/MAP and the total ICP (area under curve) during electrostimulation of the cavernous nerves at 12 weeks after IGFBP-3 shRNA administration. The representative ICP tracing in response to electrostimulation of the cavernous nerves is shown in [Figure 1(A--C)](#f1-medscimonit-21-94){ref-type="fig"}. Electrostimulation elicited significantly increased ICP/MAP ratio ([Figure 1D](#f1-medscimonit-21-94){ref-type="fig"}) and total ICP ([Figure 1E](#f1-medscimonit-21-94){ref-type="fig"}) in the IGFBP-3 shRNA treatment group compared to those in the diabetic control group (*p*\<0.01, respectively). These data suggest that IGFBP-3 shRNA administration rehabilitated erectile function in diabetic rats.

IGFBP-3 shRNA inhibits IGFBP-3 expression in rat cavernous tissue
-----------------------------------------------------------------

Real-time qPCR analysis using GAPDH as a housekeeping gene showed that cavernous IGFBP-3 mRNA level in the IGFBP-3 shRNA treatment group was significantly lower than in the diabetic control group (*P*\<0.01, [Figure 2](#f2-medscimonit-21-94){ref-type="fig"}). Accordingly, Western blot analysis showed that cavernous IGFBP-3 protein level in the IGFBP-3 shRNA treatment group was significantly lower than in the diabetic control group (*P*\<0.01, [Figure 3](#f3-medscimonit-21-94){ref-type="fig"}, lower). These results are consistent with the results of real-time qPCR analysis and prove that IGFBP-3 shRNA inhibits IGFBP-3 expression in rat cavernous tissue.

Testosterone and cGMP concentrations in rat serum
-------------------------------------------------

Both serum testosterone and cavernous cGMP concentrations were measured by ELISA and we found that serum testosterone and cavernous cGMP concentrations were both significantly increased in the IGFBP-3 shRNA treatment group compared to those in the diabetic control group at 12 weeks after IGFBP-3 shRNA administration (*p*\<0.01, [Figure 4](#f4-medscimonit-21-94){ref-type="fig"}).

Discussion
==========

In the present study, we found that concentration of serum testosterone was significantly higher in the IGFBP-3 shRNA treatment group compared to that in the diabetic control group (*p*\<0.01) at 12 weeks after IGFBP-3 shRNA administration. These results suggest that IGFBP-3 shRNA may rehabilitate erectile function via increases of concentrations of serum testosterone and cavernous cGMP in STZ-induced diabetic rats.

The possibility that hypogonadism might contribute to diabetes mellitus (DM)-related ED has been reconsidered recently, because of a higher prevalence of low testosterone in diabetic than in nondiabetic individuals \[[@b10-medscimonit-21-94]--[@b12-medscimonit-21-94]\], and even in animal models of chemical diabetes, overt hypogonadism is often reported \[[@b4-medscimonit-21-94],[@b13-medscimonit-21-94]\].

Essentially, androgens play a dual role in the erectile process by controlling both pro-erectile and anti-erectile signaling pathways \[[@b14-medscimonit-21-94],[@b15-medscimonit-21-94]\]. On the one hand, androgens exert a positive role in the maintenance of the general architecture of the penile contractile structure. Castration induces cavernous smooth muscle atrophy and contributes to structural alteration of erectile tissue, with a relative increase in connective tissue content \[[@b16-medscimonit-21-94]--[@b18-medscimonit-21-94]\]. Furthermore, castration reduced nitric oxide (NO) and its generating enzyme NO synthase (NOS), as well as NOS-containing nerve fibers \[[@b19-medscimonit-21-94]\]. Thus, in castrated rats, erectile response is markedly impaired, but testosterone (T) reverses this deficiency \[[@b16-medscimonit-21-94],[@b17-medscimonit-21-94]\]. A recent study reported that testosterone may prevent impaired erectile function by maintaining at the control level the expression of the key enzymes involved in the erectile process, such as nNOS \[[@b20-medscimonit-21-94]\]. On the other hand, it has been recently demonstrated that androgens up-regulate the major mechanism responsible for cGMP degradation, phosphodiesterase type 5 (PDE5) \[[@b19-medscimonit-21-94]\], and PDE5 regulates the amount of cGMP available for cavernosal smooth muscle relaxation and penile erection. A clinical report demonstrated a null effect of hypogonadism on penile erection \[[@b21-medscimonit-21-94]\], probably because androgen reduction produces both decreased cGMP formation (effect on NO) and degradation (effect on PDE5) \[[@b20-medscimonit-21-94]\]. The major subcellular mechanism by which erection occurs involves NO-induced activation of soluble guanylyl cyclase (sGC) and increased cGMP concentration \[[@b22-medscimonit-21-94]\]. A significantly decreased level of cGMP in diabetes rats was associated with ED in our previous study \[[@b23-medscimonit-21-94]\]. Here, we found that serum testosterone and cavernous cGMP concentrations were both significantly increased in the IGFBP-3 shRNA treatment group compared to those in the diabetic control group at 12 weeks after IGFBP-3 shRNA administration These results suggest that IGFBP-3 shRNA may rehabilitate erectile function via increased concentration of serum testosterone and improvement of NO-cGMP signaling activities in STZ-induced diabetic rats.

IGFBP-3, conventionally thought to inhibit growth through ligand sequestration, might also be antiproliferative and proapoptotic through actions independent of the insulin-like growth factor-1 (IGF-1) receptor \[[@b19-medscimonit-21-94],[@b24-medscimonit-21-94]\]. A previous study has shown that IGFBP-3 is significantly correlated with erectile function in the diabetic rat model \[[@b25-medscimonit-21-94]\]. The increased expression of IGFBP-3 might lead to depletion of the smooth muscle density and elicit ED in patients with diabetes mellitus (DM) \[[@b26-medscimonit-21-94]\]. Since IGFBP expression is suppressed by androgens, an increase of concentration of serum testosterone might decrease the expression of IGFBP-3 (the most abundant IGFBP) \[[@b7-medscimonit-21-94]\]. Thus, hyperglycemia in combination with increased IGFBP-3 expression may have a role in the development of ED \[[@b5-medscimonit-21-94]\].

Conclusions
===========

The current study indicated that IGFBP-3 shRNA may rehabilitate erectile function via increased concentration of serum testosterone and improvement of NO-cGMP signaling activities in STZ-induced diabetic rats. Further investigation of the mechanisms by which increased concentration of serum testosterone leads to activation of NO-cGMP signaling will enrich our understanding of the pathogenesis of ED of STZ-induced diabetic rats.
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![Evaluation of erectile function. Representative ICP responses to cavernous nerves electrical stimulation at 12 weeks after IGFBP-3 shRNA treatment in the normal control group (**A**), diabetic control group (**B**) (n=9), and IGFBP-3 shRNA treatment group (C). The bold line indicates 1 min of electrical stimulation to the cavernous nerves. The data on ICP/MAP (**D**) and total ICP (the area under curve) (**E**) were collected from 9 rats in each group. \* *p*\<0.01, compared to diabetic control. MAP: mean arterial pressure; ICP: intracavernous pressure.](medscimonit-21-94-g001){#f1-medscimonit-21-94}

![IGFBP-3 shRNA inhibits IGFBP-3 mRNA and protein expression in rat cavernous tissue. Quantitative real-time PCR analysis of IGFBP-3 mRNA level in rat cavernous tissue at 12 weeks after intracavernous administration of IGFBP-3 shRNA. Western blot analysis of IGFBP-3 protein level in rat cavernous tissue of normal control (lane 1), diabetic control (lane 2), and IGFBP-3 shRNA treatment group (lane 3) at 12 weeks after intracavernous administration of IGFBP-3 shRNA. The data were collected from 9 rats in each group. \* P\<0.01, compared to diabetic control, respectively.](medscimonit-21-94-g002){#f2-medscimonit-21-94}

![Testosterone concentrations in rat serum. Testosterone concentrations in rat serum at 12 weeks after IGFBP-3 shRNA treatment were determined by ELISA. The data were collected from 9 rats in each group. \* *p*\<0.01, compared to diabetic control.](medscimonit-21-94-g003){#f3-medscimonit-21-94}

![cGMP concentrations in rat cavernous tissue. cGMP concentrations in rat penile tissue at 12 weeks after IGFBP-3 shRNA treatment were determined by ELISA. The data were collected from 9 rats in each group. \* *p*\<0.01, compared to diabetic control.](medscimonit-21-94-g004){#f4-medscimonit-21-94}

###### 

Total body weight and blood glucose level in rats of three groups (n=9).

                          Normal control                                            Diabetes                                                   IGFBP-3 shRNA treatment
  ----------------------- --------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------
  Weight (g)                                                                                                                                   
   Initial                319±3                                                     314±2                                                      319± 4
   Final                  540±4[\*](#tfn2-medscimonit-21-94){ref-type="table-fn"}   258±7[\*](#tfn2-medscimonit-21-94){ref-type="table-fn"}    267±8[\*](#tfn2-medscimonit-21-94){ref-type="table-fn"}
  Blood glucose (mg/dL)                                                                                                                        
   Initial                93±6                                                      103±8                                                      107±5
   Final                  105±2                                                     307±11[\*](#tfn2-medscimonit-21-94){ref-type="table-fn"}   318±14[\*](#tfn2-medscimonit-21-94){ref-type="table-fn"}

Data were expressed as mean ±SD.

*p*\<0.01, compared to initial.
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